HiberCell
Présence
HiberCell a 7 filiales dont Genuity Science, WuXi Advanced Therapies et WuXi AppTec.
Dirigeants
Voir l'organigramme avec ses 95 principaux dirigeants
Biographies les plus recherchées chez HiberCell
- Jonathan Lanfear, President and Chief Executive Officer
- Colin Goddard, Director
- Steven Gillis, Chairman of the Board
Créer une alerte
pour suivre les mouvements de dirigeants chez HiberCell.
Biotechnologie
HiberCell a 2 284 concurrents dont Lonza (Suisse), Eurofins (Luxembourg) et Adaptive Phage Therapeutics (Etats—Unis).
Actualités en fusion/acquisition en Biotechnologie.
- Karius vient d'annoncer une levée de fonds de 100 millions de dollars. (publié le 3 mai 2024).
- Transcarent vient d'annoncer une levée de fonds de 126 millions de dollars. (publié le 2 mai 2024).
- WindRose Health Investors has announced the acquisition of SubjectWell (publié le 2 mai 2024).
Contacts en Biotechnologie
Actualités
Derniers communiqués de presse par HiberCell
- HiberCell, Inc. Announces Clinical Collaboration with Merck to Evaluate HC-7366, an Activator of ISR Kinase GCN2, in Combination with WELIREG® (belzutifan) in a Phase 1b Study of Patients with Clear Cell Renal Cell Carcinoma (ccRCC) - HiberCell
- HiberCell Announces Successful Completion and Interim Results of Phase 1 Study of Novel PERK Inhibitor, HC-5404, in Solid Tumors and Maps Forward Path as Monotherapy and in Combinations - HiberCell
- HiberCell Doses First Patient in Phase 1b Study Exploring Novel Combination of Odetiglucan and CD40 Agonistic Monoclonal Antibody (CDX-1140) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) in the Maintenance Setting - HiberCell
- HiberCell to Present Pre-clinical Data on its Novel GCN2 Activator and PERK Inhibitor Programs at the American Association for Cancer Research (AACR) Annual Meeting 2023 - HiberCell
- HiberCell to Present Pre-clinical Data on its Novel GCN2 Activator and PERK Inhibitor Programs at the American Association for Cancer Research (AACR) Annual Meeting 2023 - HiberCell
- HiberCell Maps Forward Path for Novel GCN2 Activator, HC-7366 in Acute Myeloid Leukemia (AML) - HiberCell
- HiberCell to Present Preclinical Data from Novel GCN2 Activator and PERK Inhibitor Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting - HiberCell
- HiberCell to Present Posters on Novel Candidates Odetiglucan and HC-7366 at the 2022 Annual American Society of Clinical Oncology Meeting - HiberCell
- HiberCell and the University of Pennsylvania Present Preclinical Anti-Metastatic Monotherapy Activity Data in Mice for Odetiglucan in Pancreatic Cancer at AACR Annual Meeting 2022 - HiberCell
- HiberCell Announces First Patients Dosed in Phase 2 Clinical Trial of Odetiglucan in Combination with KEYTRUDA® (pembrolizumab) in Adult Patients with Metastatic, Hormone-Refractory Breast Cancer - HiberCell
- Voir plus de communiqués de presse Close
Réseaux sociaux à propos de HiberCell
- HiberCell sur Wikipédia, Google News & Yahoo Finance en 1-click
- HiberCell sur LinkedIn, Twitter & YouTube en 1-click
Entrer en contact
Contacter par email ses dirigeants dont Jonathan Lanfear 
Appelez HiberCell au +1 212...
